Q32 reports maintained hair-growth responses after treatment withdrawal

Q32 Bio ($QTTB) reported new off-treatment follow-up from the open-label Part B of its SIGNAL-AA study of bempikibart for severe alopecia areata. Among 12 patients who had shown hair growth by the end of 36 weeks of treatment and entered follow-up, all maintained response through 16 weeks without dosing under the study’s definition. Responses deepened in 42% of that subgroup.

The findings could inform less frequent maintenance dosing as Q32 prepares a registration-directed program for the first half of 2027, subject to regulatory discussions. However, Part B enrolled only 33 patients and lacked a placebo control; the 12-person analysis is a selected responder subgroup, not the entire trial population. The company reported no treatment-related serious or grade-three-or-higher adverse events. Bempikibart remains experimental and has not secured marketing approval.

Sources:

• Company release via PR Newswire